Matinas BioPharma Holdings (NYSEAM:MTNB) - Share price, News & Analysis

MTNB fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

MTNB Stock Overview

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.

Rewards

Revenue is forecast to grow 85.2% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Matinas BioPharma Holdings Competitors

AbbVie

NYSE:ABBV

US$274.7b

Amgen

NasdaqGS:AMGN

US$130.3b

Gilead Sciences

NasdaqGS:GILD

US$78.1b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$70.6b

Price History & Performance

Summary of all time highs, changes and price drops for Matinas BioPharma Holdings
Historical stock prices
Current Share Price	US$0.67
52 Week High	US$1.61
52 Week Low	US$0.49
Beta	2.16
1 Month Change	-26.53%
3 Month Change	-4.50%
1 Year Change	-17.90%
3 Year Change	-33.14%
5 Year Change	-78.08%
Change since IPO	-48.57%

Shareholder Returns

	MTNB	US Biotechs	US Market
7D	2.5%	4.8%	0.7%
1Y	-17.9%	-22.0%	-10.8%

Return vs Industry: MTNB exceeded the US Biotechs industry which returned -22% over the past year.

Return vs Market: MTNB underperformed the US Market which returned -10.8% over the past year.

Price Volatility

Is MTNB's price volatile compared to industry and market?
MTNB volatility
MTNB Average Weekly Movement	14.8%
Biotechs Industry Average Movement	12.3%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	2.9%

Stable Share Price: MTNB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: MTNB's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2013	31	Jerry Jabbour	https://www.matinasbiopharma.com

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Matinas BioPharma Holdings Fundamentals Summary

How do Matinas BioPharma Holdings's earnings and revenue compare to its market cap?
MTNB fundamental statistics
Market Cap	US$143.13m
Earnings (TTM)	-US$24.49m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-5.9x

P/E Ratio

Is MTNB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MTNB income statement (TTM)
Revenue	US$0
Cost of Revenue	US$16.32m
Gross Profit	-US$16.32m
Other Expenses	US$8.17m
Earnings	-US$24.49m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.11
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did MTNB perform over the long term?

See historical performance and comparison

Valuation

Is Matinas BioPharma Holdings undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

3.04x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MTNB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MTNB's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: MTNB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MTNB is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MTNB's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: MTNB is overvalued based on its PB Ratio (3x) compared to the US Biotechs industry average (1.4x).

Future Growth

How is Matinas BioPharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

67.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MTNB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MTNB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MTNB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MTNB's revenue (85.2% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: MTNB's revenue (85.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MTNB's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Matinas BioPharma Holdings performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

3.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MTNB is currently unprofitable.

Growing Profit Margin: MTNB is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MTNB is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.

Accelerating Growth: Unable to compare MTNB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MTNB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: MTNB has a negative Return on Equity (-50.97%), as it is currently unprofitable.

Financial Health

How is Matinas BioPharma Holdings's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MTNB's short term assets ($45.1M) exceed its short term liabilities ($3.8M).

Long Term Liabilities: MTNB's short term assets ($45.1M) exceed its long term liabilities ($4.3M).

Debt to Equity History and Analysis

Debt Level: MTNB is debt free.

Reducing Debt: MTNB has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MTNB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MTNB has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 15.2% each year.

Dividend

What is Matinas BioPharma Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MTNB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MTNB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MTNB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MTNB's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MTNB has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure

CEO

Jerry Jabbour (47 yo)

6.17yrs

Tenure

US$3,693,314

Compensation

Mr. Jerome D. Jabbour, also known as Jerry, J.D., Co Founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016. M...

CEO Compensation Analysis

Compensation vs Market: Jerry's total compensation ($USD3.69M) is above average for companies of similar size in the US market ($USD772.03K).

Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: MTNB's management team is considered experienced (3.5 years average tenure).

Board Members

Experienced Board: MTNB's board of directors are considered experienced (4.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.2%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/17 00:00
End of Day Share Price	2022/05/17 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31